Barbara B. Bendlin

Barbara B. Bendlin

Auto-generated profile, based on publicly available information

Barbara B. Bendlin

Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NVNicholas M. Vogt
Nicholas M. Vogt
RKRobert L. Kerby
Robert L. Kerby
KDKimberly A. Dill-McFarland
Kimberly A. Dill-McFarland
SHSandra J. Harding
Sandra J. Harding
AMAndrew P. Merluzzi
Andrew P. Merluzzi
FRFederico E. Rey
Federico E. Rey
Alzheimer’s disease (AD) is the most common form of dementia. However, the etiopathogenesis of this devastating disease is not fully understood. Recent studies in rodents suggest that alterations in the gut microbiome may contribute to amyloid deposition, yet the microbial communities associated with AD have not been characterized in humans. Towards this end, we characterized the bacterial taxonomic composition of fecal samples from participants with and without a diagnosis of dementia due to AD. Our analyses revealed that the gut microbiome of AD participants has decreased microbial diversity and is compositionally distinct from control age- and sex-matched individuals. We identified phylum- through genus-wide differences in bacterial abundance including decreased Firmicutes, increased Bacteroidetes, and decreased Bifidobacterium in the microbiome of AD participants. Furthermore, we observed correlations between levels of differentially abundant genera and cerebrospinal fluid (CSF) biomarkers of AD. These findings add AD to the growing list of diseases associated with gut microbial alterations, as well as suggest that gut bacterial communities may be a target for therapeutic intervention.

22 December 2018 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
NVNicholas M. Vogt
Nicholas M. Vogt
KRKymberleigh A. Romano
Kymberleigh A. Romano
BDBurcu F. Darst
Burcu F. Darst
CECorinne D Engelman
Corinne D Engelman
SJSterling C. Johnson
Sterling C. Johnson
FRFederico E. Rey
Federico E. Rey
Trimethylamine N-oxide (TMAO), a small molecule produced by the metaorganismal metabolism of dietary choline, has been implicated in human disease pathogenesis, including known risk factors for Alzheimer’s disease (AD), such as metabolic, cardiovascular, and cerebrovascular disease. In this study, we tested whether TMAO is linked to AD by examining TMAO levels in cerebrospinal fluid (CSF) collected from a large sample (n = 410) of individuals with Alzheimer’s clinical syndrome (n = 40), individuals with mild cognitive impairment (MCI) (n = 35), and cognitively-unimpaired individuals (n = 335). Linear regression analyses were used to determine differences in CSF TMAO between groups (controlling for age, sex, and APOE ε4 genotype), as well as to determine relationships between CSF TMAO and CSF biomarkers of AD (phosphorylated tau and beta-amyloid) and neuronal degeneration (total tau, neurogranin, and neurofilament light chain protein). CSF TMAO is higher in individuals with MCI and AD dementia compared to cognitively-unimpaired individuals, and elevated CSF TMAO is associated with biomarkers of AD pathology (phosphorylated tau and phosphorylated tau/Aβ42) and neuronal degeneration (total tau and neurofilament light chain protein). These findings provide additional insight into gut microbial involvement in AD and add to the growing understanding of the gut–brain axis.

1 September 2015 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
AWAuriel A. Willette
Auriel A. Willette
BBBarbara B. Bendlin
Barbara B. Bendlin
ESErika J. Starks
Erika J. Starks
ABAlex C. Birdsill
Alex C. Birdsill
SJSterling C. Johnson
Sterling C. Johnson
SASanjay Asthana
Sanjay Asthana
Glucoregulatory impairment has reached epidemic proportions in the United States. According to the American Diabetes Association,1 29.1 million individuals in the United States have diabetes mellitus, and more than half of adults older than 64 years have prediabetes. Type 2 diabetes mellitus increases the risk for Alzheimer disease (AD), and clinical and preclinical hypergylcemia are characterized by insulin resistance. Insulin resistance is broadly defined as reduced tissue responsiveness to the action of insulin.2 Insulin, a key hormone involved in carbohydrate metabolism, facilitates microvascular blood flow, glucose uptake, and glucose oxidation for adenosine-5′-triphosphate generation.3

6 April 2020 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
HZHenrik Zetterberg
Henrik Zetterberg
BBBarbara B. Bendlin
Barbara B. Bendlin

1 August 2008 in NeuroImage
Verified
Journal Article
Closed access
BBBarbara B. Bendlin
Barbara B. Bendlin
MRMichele L. Ries
Michele L. Ries
MLMariana Lazar
Mariana Lazar
AAAndrew L. Alexander
Andrew L. Alexander
RDRobert J. Dempsey
Robert J. Dempsey
SJSterling C. Johnson
Sterling C. Johnson

17 July 2014 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
AWAuriel A. Willette
Auriel A. Willette
SJSterling C. Johnson
Sterling C. Johnson
ABAlex C. Birdsill
Alex C. Birdsill
MSMark A. Sager
Mark A. Sager
BCBradley Christian
Bradley Christian
BBBarbara B. Bendlin
Barbara B. Bendlin